Delfi Diagnostics

Delfi Diagnostics Delfi diagnostics is a company that develops and commercializes a liquid biopsy test based on fragmentomics technology and machine learning to detect early stage cancers. learn about their clinical trial, science, products, and leadership team. A new approach to screening existing screening methods and tests depend on detecting known cancer associated mutations and alterations. learn how delfi’s scalable approach quickly scans millions more data points to detect previously unrecognized cancer associated cell free dna fragments.

Delfi Diagnostics Employee Perks Benefits Levels Fyi About us delfi uses ai, machine learning and whole genome sequencing to sensitively detect unique patterns of dna fragmentation in the blood of patients with cancer. Information on valuation, funding, cap tables, investors, and executives for delfi diagnostics. use the pitchbook platform to explore the full profile. Delfi diagnostics is a series b company based in baltimore (united states), founded in 2019 by victor velculescu. it operates as a provider of dna sequencing for cancer detection. Delfi diagnostics is a biotechnology company pioneering a new class of high performance, accessible liquid biopsy tests for early cancer detection and monitoring. the company utilizes a proprietary 'fragmentomics' platform that analyzes cell free dna (cfdna) fragmentation patterns across the whole genome using machine learning, offering a cost effective and scalable approach to cancer.

Delfi Diagnostics Announces Availability Of New Fragmentome Based Delfi diagnostics is a series b company based in baltimore (united states), founded in 2019 by victor velculescu. it operates as a provider of dna sequencing for cancer detection. Delfi diagnostics is a biotechnology company pioneering a new class of high performance, accessible liquid biopsy tests for early cancer detection and monitoring. the company utilizes a proprietary 'fragmentomics' platform that analyzes cell free dna (cfdna) fragmentation patterns across the whole genome using machine learning, offering a cost effective and scalable approach to cancer. Delfi diagnostics is dedicated to saving lives through early cancer detection using their innovative fragmentomics platform. their technology allows for non invasive liquid biopsy analysis, which helps detect cancer associated dna fragments not identified by existing methods. Delfi diagnostics detects cancer early, when it is most curable, using high precision non invasive blood tests. it uses artificial intelligence and genome sequencing to detect unique patterns of dna fragmentation in the blood of patients. Delfi unleashes the power of machine learning and next generation liquid biopsies to detect cancer in a whole new way. delfi’s technology was developed to help people live longer, healthier, cancer free lives by detecting cancer early—when it’s asymptomatic but easier to cure. Discover company info on delfi diagnostics, inc. in dallas, tx, such as contacts, addresses, reviews, and registered agent.